From peptide 2° structures to small molecule inhibitors: the Edelris Discovery ENgine (EDEN)

webinar

Wed, 04 Nov 2015, 16:00 CET (Berlin)

Dr. Didier Roche, Edelris France

From peptide 2° structures to small molecule inhibitors: the Edelris Discovery ENgine (EDEN)

Edelris has pioneered for the past decade the design and synthesis of innovative, natural product-like small molecules (Keymical CollectionsTM) and generated its own Keymical SpaceTM representing over 8 M cpds. The EDEN platform (Edelris Discovery ENgine) has been developed to combine the leading role of structural information in drug discovery with the attractiveness of our Keymical SpaceTM in order to design compounds exploring new boundaries in the modulation of biological systems and particularly to address PPIs.

We will present in this webinar the approach used to design compounds mimicking alpha helix peptide secondary structures. 3D-Pharmacophore data mining using ReCore proved to be successful to discover original and drug-like modulators of the MDM2/P53 interaction.

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on